Welcome to LookChem.com Sign In|Join Free

CAS

  • or

264209-16-7

Post Buying Request

264209-16-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

264209-16-7 Usage

Description

3-AMINO-5-CYCLOPENTYL-2H-PYRAZOLE is a heterocyclic chemical compound that is part of the pyrazole family. It features a five-membered ring structure with four carbon atoms and one nitrogen atom, and is distinguished by the presence of an amino group and a cyclopentyl group. 3-AMINO-5-CYCLOPENTYL-2H-PYRAZOLE serves as a crucial building block in the synthesis of pharmaceutical drugs, agrochemicals, and other organic compounds due to its unique structure and reactivity, making it an important intermediate in the production of a variety of chemical compounds.

Uses

Used in Pharmaceutical Industry:
3-AMINO-5-CYCLOPENTYL-2H-PYRAZOLE is used as a key intermediate in the synthesis of various pharmaceutical drugs. Its unique structure allows for the development of new drug candidates with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 3-AMINO-5-CYCLOPENTYL-2H-PYRAZOLE is utilized as a versatile building block for creating a wide range of organic compounds. Its reactivity and structural features make it suitable for the formation of complex molecular architectures.
Used in Agrochemical Industry:
3-AMINO-5-CYCLOPENTYL-2H-PYRAZOLE is also used as a starting material in the development of agrochemicals. Its incorporation into the molecular structures of these compounds can lead to the creation of new pesticides or herbicides with improved efficacy and selectivity.

Check Digit Verification of cas no

The CAS Registry Mumber 264209-16-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,6,4,2,0 and 9 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 264209-16:
(8*2)+(7*6)+(6*4)+(5*2)+(4*0)+(3*9)+(2*1)+(1*6)=127
127 % 10 = 7
So 264209-16-7 is a valid CAS Registry Number.
InChI:InChI=1/C8H13N3/c9-8-5-7(10-11-8)6-3-1-2-4-6/h5-6H,1-4H2,(H3,9,10,11)

264209-16-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 5-cyclopentyl-1H-pyrazol-3-amine

1.2 Other means of identification

Product number -
Other names 5-cyclopentyl-2H-pyrazol-3-amine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:264209-16-7 SDS

264209-16-7Relevant articles and documents

Dual-inhibitors of N-Myc and AURKA as potential therapy for neuroendocrine prostate cancer

Ban, Fuqiang,Cherkasov, Artem,Lallous, Nada,Leblanc, Eric,Lee, Joseph,Morin, Hélène,Singh, Kriti,Ton, Anh-Tien

, p. 1 - 19 (2020/11/11)

Resistance to androgen-receptor (AR) directed therapies is, among other factors, associated with Myc transcription factors that are involved in development and progression of many cancers. Overexpression of N-Myc protein in prostate cancer (PCa) leads to its transformation to advanced neuroendocrine prostate cancer (NEPC) that currently has no approved treatments. N-Myc has a short half-life but acts as an NEPC stimulator when it is stabilized by forming a protective complex with Aurora A kinase (AURKA). Therefore, dual-inhibition of N-Myc and AURKA would be an attractive therapeutic avenue for NEPC. Following our computer-aided drug discovery approach, compounds exhibiting potent N-Myc specific inhibition and strong anti-proliferative activity against several N-Myc driven cell lines, were identified. Thereafter, we have developed dual inhibitors of N-Myc and AURKA through structure-based drug design approach by merging our novel N-Myc specific chemical scaffolds with fragments of known AURKA inhibitors. Favorable binding modes of the designed compounds to both N-Myc and AURKA target sites have been predicted by docking. A promising lead compound, 70812, demonstrated low-micromolar potency against both N-Myc and AURKA in vitro assays and effectively suppressed NEPC cell growth.

MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN

-

Paragraph 00125, (2020/09/08)

Disclosed herein are compounds and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of disease where modulation of Myc family proteins is desired. Also disclosed herein are methods of using said compounds and compositions.

AURORA KINASE INHIBITORS

-

Paragraph 0256, (2014/12/12)

Disclosed herein inter alia are compositions and methods useful in the treatment of cancer and for modulating the activity of Aurora A kinase and/or a Myc family protein.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 264209-16-7